Last Updated on December 31, 2023 by The Health Master
Alembic Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic version of Fesoterodine fumarate extended-release tablets, used for overactive bladder in adults with symptoms of urinary incontinence, urgency, and frequency.
The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for fesoterodine fumarate extended-release tablets is for strengths of 4 mg and 8 mg, the company said in a statement.
“The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Toviaz Extended-Release Tablets, 4 mg and 8 mg, of Pfizer Inc,” it added.
These tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.
“It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses,” Alembic said.
Citing IQVIA data, the company said fesoterodine fumarate extended-release tablets, 4 mg and 8 mg have an estimated market size of USD 225 million for 12-months ending September 2021.
Alembic said it has received 20 approvals (14 final approvals and 6 tentative approvals) year-to-date and a cumulative total of 159 abbreviated new drug application (ANDA) approvals from USFDA.
USFDA gives nod to Granules Pharma for potassium chloride for oral solution
USFDA gives nod to Glenmark this for Blood Pressure drug
USFDA gives Orphan Drug Designation to Eplontersen
USFDA’s response on Chronic Cough treatment
USFDA gives nod to FDC for Ofloxacin Otic Solution
USFDA gives conditional nod to Glenmark for generic Regadenoson injection
Panacea sells domestic formulation assets to Mankind Pharma
Pharma distributor among 3 held for illegal sale of Anesthetic drugs
IPC flags safety alert against most common Drug Ibuprofen – NSAID
Govt invites third round of applications under PLI Scheme for domestic API manufacturing
USFDA issues 3 observations to Granules Pharmaceuticals Inc
Blaine Labs recalled of RevitaDerm Wound Care Gel Due to this reason
NPPA seeks clarification on license status of clotrimazole 1% mouth paint
China to strengthen anti-monopoly efforts in Pharma industry
USFDA gives nod to Granules Pharma for potassium chloride for oral solution
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
